Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 5 (2008), Issue 9 (September)

1. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study.
   Lancet Oncol, 9(9): 831-9. [Abstract] [Full-text]
2. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.
   Int J Cancer, 123(9): 2222-7. [Abstract] [Full-text]
3. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
   Clin Cancer Res, 14(17): 5619-25. [Abstract] [Full-text]
4. Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
   Clin Cancer Res, 14(17): 5585-93. [Abstract] [Full-text]
5. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy.
   J Clin Oncol, 26(26): 4326-32. [Abstract] [Full-text]
6. Expression and role of DJ-1 in leukemia.
   Biochem Biophys Res Commun, 375(3): 477-83. [Abstract] [Full-text]
7. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
   Cancer, 113(6): 1370-8. [Abstract] [Full-text]
8. CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.
   Int J Cancer, 123(10): 2321-6. [Abstract] [Full-text]
9. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
   Leuk Res, 32(12): 1800-8. [Abstract] [Full-text]
10. Bone marrow cell cycle markers in inherited bone marrow failure syndromes.
    Leuk Res, 32(12): 1793-9. [Abstract] [Full-text]
11. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Leuk Res, 32(12): 1830-6. [Abstract] [Full-text]
12. Nuclear organization of PML bodies in leukaemic and multiple myeloma cells.
    Leuk Res, 32(12): 1866-77. [Abstract] [Full-text]
13. Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members.
    Leuk Res, 32(12): 1820-3. [Abstract] [Full-text]
14. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
    Blood, 112(7): 2896-905. [Abstract] [Full-text]
15. MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks.
    Mol Cell Biol, 28(19): 5912-23. [Abstract] [Full-text]
16. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
    Blood, 112(7): 2886-95. [Abstract] [Full-text]
17. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Cancer, 113(7): 1596-604. [Abstract] [Full-text]
18. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
    Cancer, 113(7): 1605-13. [Abstract] [Full-text]
19. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Eur J Haematol, 81(4): 259-66. [Abstract] [Full-text]
20. Capillary gel electrophoresis: a simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia.
    Eur J Haematol, 81(4): 273-80. [Abstract] [Full-text]
21. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Eur J Haematol, 81(4): 281-8. [Abstract] [Full-text]
22. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.
    Ann Hematol, 87(11): 881-5. [Abstract] [Full-text]
23. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
    Ann Hematol, 87(11): 887-90. [Abstract] [Full-text]
24. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
    J Clin Oncol, 26(28): 4603-9. [Abstract] [Full-text]
25. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
    J Clin Oncol, 26(28): 4595-602. [Abstract] [Full-text]

© 2004-2012 Acute Myeloid Leukemia Research Today. All Rights Reserved.